Download Resistance Publications from July 2008 to September 2008

Resistance Publications from July 2008 to September
2008
Title
Author
Journal
1) Origin and evolutionary history of HIV-1
subtype C in Brazil.
Bello, Gonzalo
AIDS - October 1, 2008, Volume 22,
Issue 15
2) On the origin of HIV-1 subtype C in South
America.
Fontella, Rachel
AIDS - October 1, 2008, Volume 22,
Issue 15
Bénédicte Roquebert
AIDS - October 1, 2008, Volume 22,
Issue 15 (Correspondence, no
abstract)
3) Selection of the Q148R integrase inhibitor
resistance mutation in a failing raltegravir
containing regimen.
4) Pattern and impact of emerging resistance
mutations in treatment experienced patients
failing darunavir-containing regimen.
Delaugerre, Constance
AIDS - September 12, 2008, Volume
22, Issue 14
5) The epidemic origin and molecular
properties of B': a founder strain of the HIV1 transmission in Asia.
Deng, Xiang
AIDS - September 12, 2008, Volume
22, Issue 14
6) Probing the sequence space available for
HIV-1 evolution.
ter Brake, Olivier
AIDS - September 12, 2008, Volume
22, Issue 14
7) Clade-specific HIV-1 integrase
polymorphisms do not reduce raltegravir
and elvitegravir phenotypic susceptibility.
Van Baelen
AIDS - September 12, 2008, Volume
22, Issue 14
8) Correlation between genotypic predictions
based on V3 sequences and phenotypic
determination of HIV-1 tropism.
Raymond, Stephanie
AIDS - September 12, 2008, Volume
22, Issue 14
9) Human leukocyte antigen-specific
polymorphisms in HIV-1 Gag and their
association with viral load in chronic
untreated infection.
Brumme, Zabrina L
AIDS - July 11, 2008 Volume 22, Issue
11
10) Early virological suppression with threeclass antiretroviral therapy in HIV-infected
African infants.
Prendergast, Andrew
AIDS - July 11, 2008, Volume 22,
Issue 11
11) Transmission of HIV-1 minority-resistant
variants and response to first-line
antiretroviral therapy.
Peuchant, Olivia
AIDS - July 31, 2008, Volume 22,
Issue 12
12) Interplay of Reverse Transcriptase Inhibitor
Therapy and Gag p6 Diversity in HIV Type 1
Subtype G and CRF02_AG
Akinyemi I. Ojesina
AIDS Research and Human
Retroviruses, September 2008,
Volume 24, Issue 9
13) Analysis of Nevirapine Resistance
Mutations in Cloned HIV Type 1 Variants
from HIV-Infected Ugandan Infants Using a
Single-Step Amplification-Sequencing
Method (AmpliSeq)
William Ian Towler
AIDS Research and Human
Retroviruses, September 2008,
Volume 24, Issue 9
14) Examination of a Second Region of the HIV
Type 1 Genome Reveals Additional Cases of
Superinfection
Anne Piantadosi
AIDS Research and Human
Retroviruses, September 2008,
Volume 24, Issue 9
15) Analysis of Near Full-Length Genomic
Sequences of Drug-Resistant HIV-1
Spreading among Therapy-Naïve Individuals
in Nagoya, Japan: Amino Acid Mutations
Associated with Viral Replication Activity
Shiro Ibe
AIDS Research and Human
Retroviruses, August 2008, Volume
24, Issue 8
16) Molecular Epidemiology Demonstrated
Three Emerging Clusters of Human
Immunodeficiency Virus Type 1 Subtype B
Infection in Hong Kong
AIDS Research and Human
Retroviruses, July 2008, Volume 24,
Issue 7
Tommy W.C. Leung
17) Use of Tissue Culture Cell Lines to Evaluate
HIV Antiviral Resistance
Halina Krowicka
AIDS Research and Human
Retroviruses, July 2008, Volume 24,
Issue 7
18) Short Communication: Profiling ResistanceRelated Mutations in the Protease Region of
the pol Gene: Single Genome Sequencing of
HIV in Plasma and Peripheral Blood
Mononuclear Cells
Ana Paula Guimaraes
AIDS Research and Human
Retroviruses, July 2008, Volume 24,
Issue 7
19) Mechanisms of Human Immunodeficiency
Virus Type 1 Concerted Integration Related
to Strand Transfer Inhibition and Drug
Resistance
Jacob A. Zahm
Antimicrobial Agents and
Chemotherapy, September 2008,
Volume 52, Issue 9
20) Pharmacokinetics of High-Dose LopinavirRitonavir with and without Saquinavir or
Nonnucleoside Reverse Transcriptase
Inhibitors in Human Immunodeficiency
Virus-Infected Pediatric and Adolescent
Patients Previously Treated with Protease
Inhibitors
Brian L. Robbins
Antimicrobial Agents and
Chemotherapy, September 2008,
Volume 52, Issue 9
Anne-Genevieve Marcelin
Antimicrobial Agents and
Chemotherapy, September 2008,
Volume 52, Issue 9
21) Tipranavir-Ritonavir Genotypic Resistance
Score in Protease Inhibitor-Experienced
Patients
22) Population trends in the prevalence and
patterns of protease resistance related to
exposure to unboosted and boosted
protease inhibitors
The UK Collaborative Group
on HIV Drug Resistance and
the UK Collaborative HIV
Cohort Study
Antiviral Therapy, Volume 13, Issue 6
23) Effect of tenofovir subtraction on HIV
plasma viraemia, CD4+ T-cell count and
resistance in a patient with baseline K65R
and M184V mutations
Ricky Hsu
Antiviral Therapy, Volume 13, Issue 5
24) The status of HIV-1 resistance to
antiretroviral drugs in sub-Saharan Africa
Raph L Hamers
Antiviral Therapy, Volume 13, Issue 5
25) Comparison of raltegravir and elvitegravir
on HIV-1 integrase catalytic reactions and
on a series of drug-resistant integrase
mutants.
Marinello, J
Biochemistry. September 9, 2008,
Volume 47, Issue 36
26) Emergence of Drug Resistance in HIV Type
1–Infected Patients after Receipt of FirstLine Highly Active Antiretroviral Therapy: A
Systematic Review of Clinical Trials
Ravindra Gupta
Clinical Infectious Diseases,
September 1, 2008, Volume 47, Issue
5
27) Detection of Nonnucleoside ReverseTranscriptase Inhibitor–Resistant HIV-1 after
Discontinuation of Virologically Suppressive
Antiretroviral Therapy
C. Bradley Hare
Clinical Infectious Diseases, August 1,
2008, Volume 47, Issue 3
28) Antiretroviral Drug Resistance Testing in
Adult HIV-1 Infection: 2008
Recommendations of an International AIDS
Society–USA Panel
Martin S. Hirsch
Clinical Infectious Diseases, July 15,
2008, Volume 47, Issue 2
29) Maraviroc: The First of a New Class of
Antiretroviral Agents
Clinical Infectious Diseases, July 15,
2008, Volume 47, Issue 2
Rodger D. MacArthur
30) Drug resistance profiles for the HIV
integrase gene in patients failing raltegravir
salvage therapy.
Charpentier, C
HIV Medicine (EPub ahead of print)
31) Impact of reverse transcriptase resistance
on the efficacy of TMC125 (etravirine) with
two nucleoside reverse transcriptase
inhibitors in protease inhibitor-naïve,
nonnucleoside reverse transcriptase
inhibitor-experienced patients: study
TMC125-C227.
HIV Medicine (Epub ahead of print)
Ruxrungtham, K
32) Secure antiretroviral therapy delivery in a
resource-limited setting: streamlined to
minimize drug resistance and expense
D Kitkungvan
HIV Medicine, September 2008,
Volume 9, Issue 8
33) Prediction of phenotypic susceptibility to
antiretroviral drugs using physiochemical
properties of the primary enzymatic
structure combined with artificial neural
networks
J Kjær
HIV Medicine, September 2008,
Volume 9, Issue 8
34) New mutations associated with resistance
not detected following zidovudine
monotherapy in pregnancy when used in
accordance with British HIV Association
guidelines
P Read
HIV Medicine, August 2008, Volume 9,
Issue 7
35) RNA amplification of the HIV-1 Pol and env
regions on dried serum and plasma spots R Dachraoui
HIV Medicine, August 2008, Volume 9,
Issue 7
36) The Impact of Different Definitions on the
Estimated Rate of Transmitted HIV Drug
Resistance in the United Kingdom.
JAIDS (Epub ahead of print)
Green, H
37) HIV Drug Resistance Pattern Among
HAART-Exposed Patients With Suboptimal
Virological Response in Ouagadougou,
Burkina Faso.
Tebit, Denis
JAIDS, 1 September 2008, Volume 49,
Issue 1
38) Phylogenetic Investigation of Transmission
Pathways of Drug-Resistant HIV-1 Utilizing
Pol Sequences Derived From Resistance
Genotyping.
Kaye, Matthew
JAIDS, 1 September 2008, Volume 49,
Issue 1
39) Letters to the Editor: Emergence of
Resistance Mutations Preceding Virologic
Failure in Patients Receiving Antiretroviral
Therapy.
Ricardo S Diaz
JAIDS, 1 September 2008, Volume 49,
Issue 1
40) In Vitro Characterization of MultidrugResistant HIV-1 Isolates From a Recently
Infected Patient Associated With Dual
Tropism and Rapid Disease Progression.
Mohri, Hiroshi
JAIDS 15 Aug 2008, Volume 48, Issue
5
41) Viral Dynamics and In Vivo Fitness of HIV-1
in the Presence and Absence of Enfuvirtide. Marconi, Vincent
JAIDS, 15 Aug 2008, Volume 48,
Issue 5
42) High Prevalence of Unique Recombinant
Forms of HIV-1 in Ghana: Molecular
Epidemiology From an Antiretroviral
Resistance Study.
JAIDS, 15 Aug 2008, Volume 48,
Issue 5
Delgado, Elena
43) Viral Dynamics and In Vivo Fitness of HIV-1
in the Presence and Absence of Enfuvirtide. Marconi, Vincent
JAIDS, August 15, 2008, Volume 48,
Issue 5
44) High prevalence of unique recombinant
forms of HIV-1 in Ghana: molecular
epidemiology from an antiretroviral
resistance study.
JAIDS, August 15, 2008, Volume 48,
Issue 5
Delgado, E
45) Optimization of the Oligonucleotide Ligation
Assay, a Rapid and Inexpensive Test for
Detection of HIV-1 Drug Resistance
Mutations, for Non-North American Variants. Beck, Ingrid
JAIDS, 1 Aug 2008, Volume 48, Issue
4
46) The A62V and S68G Mutations in HIV-1
Reverse Transcriptase Partially Restore the
Replication Defect Associated With the
K65R Mutation.
Svarovskaia, Evguenia S
JAIDS, 1 Aug 2008, Volume 48, Issue
4
47) HIV-2 integrase gene polymorphism and
phenotypic susceptibility of HIV-2 clinical
isolates to the integrase inhibitors
raltegravir and elvitegravir in vitro.
Roquebert, B
Journal of Antimicrobial Chemotherapy
(Epub ahead of print)
48) Impact of gag mutations on selection of
darunavir resistance mutations in HIV-1
protease.
Lambert-Niclot, S
Journal of Antimicrobial Chemotherapy
(Epub ahead of print)
49) Detection of low-frequency K103N mutants
after unstructured discontinuation of
efavirenz in the presence of the CYP2B6 516
TT polymorphism.
Garcia-Diaz, A
Journal of Antimicrobial Chemotherapy
(Epub ahead of print)
50) Shifting paradigms: the resistance profile of
etravirine
Anna Maria Geretti
Journal of Antimocrobial
Chemotherapy, October 2008, Volume
62, Issue 4
51) Low prevalence of transmitted antiretroviral
drug resistance in a large UK HIV-1 cohort Brendan A. I. Payne
Journal of Antimicrobial
Chemotherapy, September 2008,
Volume 62, Issue 3
52) Why are there different dynamics in the
selection of drug resistance in HIV and
hepatitis B and C viruses?
Vincent Soriano
Journal of Antimicrobial
Chemotherapy, July 2008, Volume 62,
Issue 1
Anne Derache
Journal of Antimicrobial
Chemotherapy, June 13, 2008,
Volume 62, Issue 3
53) Evolution of genetic diversity and drug
resistance mutations in HIV-1 among
untreated patients from Mali between 2005
and 2006
54) HIV-1-infected patients from the French
National Observatory experiencing
virological failure while receiving enfuvirtide Diane Descamps
Journal of Antimicrobial
Chemotherapy, June 13, 2008,
Volume 62, Issue 3
55) Tipranavir resistance associated mutations
in protease inhibitor-naïve patients with HIV1 subtype A/E infection.
Sungkanuparph, S
Journal of Clinical Virology (Epub
ahead of print)
56) Foscarnet salvage therapy efficacy is
associated with the presence of thymidineassociated mutations (TAMs) in HIV-infected
patients
Charlotte Charpentier
Journal of Clinical Virology, October
2008, Volume 43, Issue 2
57) The HIV-1 protease resistance mutation I50L
is associated with resistance to atazanavir
and susceptibility to other protease
inhibitors in multiple mutational contexts
P. Sista
Journal of Clinical Virology, August
2008, Volume 42, Issue 4
58) Analysis of Nevirapine (NVP) Resistance in
Ugandan Infants Who Were HIV Infected
Despite Receiving Single-Dose (SD) NVP
versus SD NVP Plus Daily NVP Up to 6
Weeks of Age to Prevent HIV Vertical
Transmission
Jessica D. Church
Journal of Infectious Diseases,
October 1, 2008, Volume 198, Issue 7
59) Characteristics of HIV Type 1 (HIV-1)
Glycoprotein 120 env Sequences in MotherInfant Pairs Infected with HIV-1 Subtype
CRF01_AE
Tanawan Samleerat
Journal of Infectious Diseases,
September 15, 2008, Volume 198,
Issue 6
60) Nevirapine Resistance in Women and
Infants after First versus Repeated Use of
Single-Dose Nevirapine for Prevention of
HIV-1 Vertical Transmission
Tamara S. Flys
Journal of Infectious Diseases, August
15, 2008, Volume 198, Issue 4
61) HIV-1 diversity among inmates of Italian
prisons
Benedetta Longo
Journal of Medical Virology, October
2008, Volume 80, Issue 10
62) Antiretroviral genotypic resistance in
plasma RNA and whole blood DNA in HIV-1
infected patients failing HAART
Annalisa Saracino
Journal of Medical Virology, October
2008, Volume 80, Issue 10
63) Structural basis for the improved drug
resistance profile of new generation
benzophenone non-nucleoside HIV-1
reverse transcriptase inhibitors.
Ren J
Journal of Medicinal Chemistry, 28
August 2008, Volume 51, Issue 16
64) Mechanistic Basis of Zidovudine
Hypersusceptibility and Lamivudine
Resistance Conferred by the Deletion of
Codon 69 in the HIV-1 Reverse
Transcriptase Coding Region
Mónica Kisic
Journal of Molecular Biology, 3
October 2008, Volume 382, Issue 2
65) Minority HIV-1 Variants in Antiretroviral
Naive Persons with Reverse Transcriptase
Codon 215 Revertant Mutations.
Mitsuya, Y
Journal of Virology (Epub ahead of
print)
66) Resistance mutations in HIV-1 integrase
selected with Elvitegravir confer reduced
susceptibility to a wide range of integrase
inhibitors.
Goethals, O
Journal of Virology (Epub ahead of
print)
67) Baseline resistance of primary HIV-1 strains
to the CXCR4 inhibitor AMD3100.
Harrison, J E
Journal of Virology (Epub ahead of
print)
68) Temporal and Spatial Dynamics of Human
Immunodeficiency Virus Type 1 Circulating
Recombinant Forms 08_BC and 07_BC in
Asia
Kok Keng Tee
Journal of Virology, September 2008,
Volume 82, Issue 18
69) In Vivo Emergence of Vicriviroc Resistance
in a Human Immunodeficiency Virus Type 1
Subtype C-Infected Subject
Athe M. N. Tsibris
Journal of Virology, August 2008,
Volume 82, Issue 16
70) Human Immunodeficiency Virus (HIV) Type
1 Proviral Hypermutation Correlates with
CD4 Count in HIV-Infected Women from
Kenya
Allison M. Land
Journal of Virology, August 2008,
Volume 82, Issue 16
71) Mechanistic Studies of a T20-Dependent
Human Immunodeficiency Virus Type 1
Variant
Chris Baldwin
Journal of Virology, August 2008,
Volume 82, Issue 15
72) Subgroup and resistance analyses of
raltegravir for resistant HIV-1 infection.
Cooper, D A
New England journal of Medicine, July
2008, Volume 359, Issue 4
73) Raltegravir with optimized background
therapy for resistant HIV-1 infection.
Steigbigel, R T
New England Journal of Medicine, July
2008, Volume 359, Issue 4
74) HIV Integrase Inhibitors — Out of the
Pipeline and into the Clinic
Diane V. Havlir
New England Journal of Medicine, July
24, 2008, Volume 359, Issue 4
75) Review of HIV antiretroviral drug resistance. Chen, T K
Pediatric Infectious Disease Journal,
Aug 2008, Volume 27, Issue 8
76) Minority HIV-1 drug resistance mutations
are present in antiretroviral treatment-naïve
populations and associate with reduced
treatment efficacy.
johnson, J A
PLoS Med. 29 July 2008 Volume 5,
Issue 7
77) Natural variation of HIV-1 group M integrase:
inplications for a new class of antiretroviral
inhibitors
Rhee, Soo-Yon
Retro Virology, 7th August 2008,
Volume 5, Issue 74
78) New and Old Complex Recombinant HIV-1
Strains among Patients with Primary
Infection in 1996-2006 in France: the French
ANRS CO06 Primo Cohort Study
Frange, Pierre
RetroVirology, 1st August 2008,
Volume 5, Issue 69
79) Drug-resistant TB and HIV in resourcelimited settings: what TB/HIV programmes
can learn from each other.
Tropical Medicine and International
Health (Epub ahead of print)
Colebunders, R